Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1434 - Efficacy of chemotherapy for elderly patients with extrapulmonary neuroendocrine carcinomas

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Chikako Funasaka

Citation

Annals of Oncology (2018) 29 (suppl_9): ix170-ix172. 10.1093/annonc/mdy433

Authors

C. Funasaka1, O. Yasushi2, Y. Kanemasa2, T. Shimoyama2

Author affiliations

  • 1 Department Of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Center Komagome Hospital, 113-8677 - Tokyo/JP
  • 2 Department Of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Center Komagome Hospital, Tokyo/JP
More

Resources

Abstract 1434

Background

Standard chemotherapy for extrapulmonary neuroendocrine carcinomas (EPNEC) is not established. Treatment for small cell lung cancer is also used for EPNEC. The efficacy of chemotherapy for elderly patients with EPNEC is not clear. The aim of this study is to estimate the efficacy of chemotherapy in the elderly with EPNEC.

Methods

We retrospectively investigated the patients of EPNEC who received 1st line platinum-based chemotherapy between April 2007 to June 2018. The time to treatment failure (TTF), the overall survival time (OST) and the efficacy of chemotherapy were compared between two groups; the elderly patients group in which patients’ age was over 70 years old (group A) and the younger patients group that age under 70 years old (group B).

Results

Among 35 patients with EPNEC, 14 patients were group A and 21 patients were group B. Median age was 75 (70-86) years old in group A, which was 60 (41-69) years old in group B. Primary site included pancreas (n = 3), gastrointestinal (n = 6), prostate (n = 2), and primary unknown (n = 3) in group A, which included pancreas (n = 4), biliary duct (n = 1), gastrointestinal (n = 8), prostate (n = 1), urothelial duct (n = 2), salivary grand (n = 1), and primary unknown (n = 4) in group B. Primary chemotherapy contained cisplatin (CDDP) + etoposide (ETP) (n = 1), carboplatin (CBDCA) + ETP (n = 7), CDDP + irinotecan (CPT-11) (n = 6) in group A, which contained CDDP + ETP (n = 5), CBDCA + ETP (n = 2), CDDP + CPT-11 (n = 14) in group B. The initial dose of chemotherapy reduced in 43% of the patients in group A, which reduced in 23% of that in group B. The Median TTF was 71.5 (25-343) days in group A and 123.0 (41-154) days in group B (p = 0.50) and the median OST was 712 (101-888) days in group A, which was 333 (165-671) days in group B (p = 0.46). One patient (7%) had complete response and 3 patients (21%) had partial response in group A, 0 patient had complete response and 13 patients (61%) had partial response in group B, and disease control rate was 69% in group A, which was 76% in group B.

Conclusions

Though the effect of chemotherapy for the elderly EPNEC patients was insufficient compared with the younger patients, the prognosis was similar to that of the younger. Many of the elderly received CBDCA + ETP and CDDP + CPT-11 regimen, these may be acceptable for the elderly EPNEC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Chikako Funasaka.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.